@Article{Lesiak2010,
journal="Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii",
issn="1642-395X",
volume="27",
number="2",
year="2010",
title="Case reportsEczema herpeticum Kaposi during treatment of a child with atopic dermatitis  with 1% pimecrolimus cream",
abstract="Atopic dermatitis (AD) is a chronic skin disease affecting approximately 10-20% of the population worldwide. Eczema herpeticum Kaposi is infectious skin eruption caused by herpes simplex viruses, occurring mostly in patients with AD. Literature data indicate that topical immunosuppressants, mainly glucocorticosteroids, but also calcineurin inhibitors, may be associated with eczema herpeticum development. We present a case of an 18-month-old boy with AD who was treated with 1% pimecrolimus cream. After 20 days of its use he developed generalized umbilicated vesiculopustules followed by erosions, located on his face, neck and dorsal part of his hands. Skin lesions were accompanied by fever, malaise and peripheral lymphadenopathy. Based on the clinical picture, the diagnosis of eczema herpeticum Kaposi was established. Treatment with intravenous acyclovir was introduced and then quick clinical improvement of skin changes was observed. The presented case might provide evidence that topical pimecrolimus may be one of the potential triggering factors in eczema herpeticum development.",
author="Lesiak, Aleksandra
and Kopeć, Aleksandra
and Chruściel, Anna
and Narbutt, Joanna",
pages="135--139",
url="https://www.termedia.pl/Case-reports-Eczema-herpeticum-Kaposi-during-treatment-of-a-child-with-atopic-dermatitis-with-1-pimecrolimus-cream,7,14813,1,1.html"
}